Effects of extended-release niacin with laropiprant in high-risk patients (HPS2-THRIVE)
HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S
Published in New England Journal of Medicine
Methodology
Randomised placebo-controlled trial of extended-release niacin with laropiprant in 25,673 adults with vascular disease on statin therapy, followed a median 3.9 years.
Key Findings
No reduction in major vascular events, with significant excesses of diabetes-related complications, infection, bleeding and gastrointestinal and musculoskeletal adverse effects.
Conclusions
Niacin adds no cardiovascular benefit on statin therapy and causes significant harm.
Limitations
Laropiprant co-administration complicates attribution of some adverse events.
Supplements Studied
Niacin with laropiprant did not reduce major vascular events and caused significant excesses of serious adverse events.
Outcomes Measured
Niacin improved lipid fractions including LDL particle characteristics but produced no reduction in major vascular events
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.